RGMB-AS1: A Non-Coding RNA Molecule as A Drug Target Or Biomarker

Target Name: RGMB-AS1

NCBI ID: G503569

RGMB-AS1

Other Name(s): RGMB antisense RNA 1

RGMB-AS1: A Non-Coding RNA Molecule as A Drug Target Or Biomarker

RNA-based therapeutics have emerged as a promising approach for treating various diseases, including cancer. One such RNA molecule is RGMB-AS1, which has been shown to have potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of RGMB-AS1 in greater detail.

RGMB-AS1: Structure and Function

RGMB-AS1 is a non-coding RNA molecule that was identified as a potential drug target or biomarker in various diseases, including cancer. It is composed of 21 amino acid residues and has a molecular weight of 23.8 kDa. RGMB-AS1 is expressed in various tissues, including liver, lung, and brain, and has been shown to play a role in various physiological processes, including cell growth, apoptosis, and inflammation.

One of the unique features of RGMB-AS1 is its ability to interact with specific protein molecules, including the protein p53. p53 is a well-known tumor suppressor protein that plays a critical role in regulating cell growth and apoptosis. RGMB-AS1 has been shown to physically interact with p53 and can modulate its activity, leading to the inhibition of cell proliferation and the inducement of apoptosis.

In addition to its interaction with p53, RGMB-AS1 has also been shown to interact with several other proteins, including the transcription factor NF-kappa-B and the protein PDGF-B. These interactions may have implications for its potential as a drug target or biomarker.

Applications: Drug Target or Biomarker

RGMB-AS1's interaction with p53 and other proteins makes it a potential drug target or biomarker. The inhibition of p53 activity by RGMB-AS1 has been shown to have therapeutic potential in various diseases, including cancer. For example, studies have shown that inhibition of p53 activity with RGMB-AS1 can lead to the inhibition of cancer cell proliferation and the inhibition of the angiogenic effect, which is the process by which cancer cells promote the formation of new blood vessels to provide oxygen and nutrients.

In addition to its potential as a drug target, RGMB-AS1 has also been shown to be a potential biomarker for various diseases, including cancer. The inhibition of p53 activity by RGMB-AS1 has been shown to be associated with the development and progression of cancer. For example, studies have shown that RGMB-AS1 expression is correlated with the poor prognosis of patients with various cancers, including breast, lung, and colorectal cancers.

Conclusion

In conclusion, RGMB-AS1 is a non-coding RNA molecule that has been shown to have potential as a drug target or biomarker in various diseases, including cancer. Its interaction with the protein p53 and other proteins makes it a promising candidate for therapeutic intervention. Further studies are needed to fully understand the biology and potential applications of RGMB-AS1.

Protein Name: RGMB Antisense RNA 1

The "RGMB-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RGMB-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets